176 related articles for article (PubMed ID: 35481791)
21. Cardiotoxicity of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: Pathophysiology, Clinical Implications, and Echocardiographic Assessment.
Nenna A; Carpenito M; Chello C; Nappi P; Annibali O; Vincenzi B; Grigioni F; Chello M; Nappi F
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897819
[TBL] [Abstract][Full Text] [Related]
22. Chimeric antigen receptor T-cell therapy for the treatment of aggressive B-cell non-Hodgkin lymphomas: efficacy, toxicity, and comparative chimeric antigen receptor products.
Hunter BD; Rogalski M; Jacobson CA
Expert Opin Biol Ther; 2019 Nov; 19(11):1157-1164. PubMed ID: 31342797
[No Abstract] [Full Text] [Related]
23. FDA investigates risk of secondary lymphomas after CAR-T immunotherapy.
Furlow B
Lancet Oncol; 2024 Jan; 25(1):21. PubMed ID: 38071995
[No Abstract] [Full Text] [Related]
24. Safety and feasibility of outpatient chimeric antigen receptor (CAR) T-cell therapy: experience from a tertiary care center.
Borogovac A; Keruakous A; Bycko M; Holter Chakrabarty J; Ibrahimi S; Khawandanah M; Selby GB; Yuen C; Schmidt S; Autry MT; Al-Juhaishi T; Wieduwilt MJ; Asch AS
Bone Marrow Transplant; 2022 Jun; 57(6):1025-1027. PubMed ID: 35411106
[No Abstract] [Full Text] [Related]
25. Determinants of response and resistance to CAR T cell therapy.
Lesch S; Benmebarek MR; Cadilha BL; Stoiber S; Subklewe M; Endres S; Kobold S
Semin Cancer Biol; 2020 Oct; 65():80-90. PubMed ID: 31705998
[TBL] [Abstract][Full Text] [Related]
26. Strategies to overcome the side effects of chimeric antigen receptor T cell therapy.
Mirzaee Godarzee M; Mahmud Hussen B; Razmara E; Hakak-Zargar B; Mohajerani F; Dabiri H; Fatih Rasul M; Ghazimoradi MH; Babashah S; Sadeghizadeh M
Ann N Y Acad Sci; 2022 Apr; 1510(1):18-35. PubMed ID: 34982476
[TBL] [Abstract][Full Text] [Related]
27. Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy Against Thoracic Malignancies: Challenges and Opportunities.
Chen L; Chen F; Niu H; Li J; Pu Y; Yang C; Wang Y; Huang R; Li K; Lei Y; Huang Y
Front Immunol; 2022; 13():871661. PubMed ID: 35911706
[TBL] [Abstract][Full Text] [Related]
28. Clinical predictors of chimeric antigen receptor T-cell therapy neurotoxicity: a single-center study.
Yuen C; Rezania K; Kelly T; Bishop MR
Immunotherapy; 2021 Oct; 13(15):1261-1269. PubMed ID: 34558978
[TBL] [Abstract][Full Text] [Related]
29. ASCO releases guideline on CAR T-cell therapy: A multidisciplinary team's recommendations help in the recognition, workup, evaluation, and management of the most common chimeric antigen receptor (CAR) T-cell-related toxicities: A multidisciplinary team's recommendations help in the recognition, workup, evaluation, and management of the most common chimeric antigen receptor (CAR) T-cell-related toxicities.
O'Rourke K
Cancer; 2022 Feb; 128(3):429-430. PubMed ID: 35050523
[No Abstract] [Full Text] [Related]
30. Resolution of persistent SARS-CoV-2 infection with prolonged intravenous remdesivir and vaccination in a patient post CAR-T.
Ambati S; Ali B; Seddon O; Godkin A; Scurr M; Moore C; Rowntree C; Underwood J
Int J Hematol; 2023 May; 117(5):765-768. PubMed ID: 36757522
[TBL] [Abstract][Full Text] [Related]
31. Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.
Schultz L
Front Immunol; 2020; 11():1985. PubMed ID: 32849662
[TBL] [Abstract][Full Text] [Related]
32. CAR T-Cell Therapy: Is CD28-CAR Heterodimerization Its Achilles' Heel?
Ferreira LMR; Muller YD
Front Immunol; 2021; 12():766220. PubMed ID: 34868017
[No Abstract] [Full Text] [Related]
33. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
Gauthier J; Yakoub-Agha I
Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
[TBL] [Abstract][Full Text] [Related]
34. Next-Generation Implementation of Chimeric Antigen Receptor T-Cell Therapy Using Digital Health.
Banerjee R; Shah N; Dicker AP
JCO Clin Cancer Inform; 2021 Jun; 5():668-678. PubMed ID: 34110929
[TBL] [Abstract][Full Text] [Related]
35. Preclinical Evaluation of Chimeric Antigen Receptor-Modified T Cells Specific to Epithelial Cell Adhesion Molecule for Treating Colorectal Cancer.
Zhang BL; Li D; Gong YL; Huang Y; Qin DY; Jiang L; Liang X; Yang X; Gou HF; Wang YS; Wei YQ; Wang W
Hum Gene Ther; 2019 Apr; 30(4):402-412. PubMed ID: 30693795
[TBL] [Abstract][Full Text] [Related]
36. Practical aspects of CAR-T cell therapy.
Jana M; Tomáš J; Michal K; Kateřina B; Juraj U; Ivo D; Zdeněk K; Roman H
Klin Onkol; 2022; 35(1):44-54. PubMed ID: 35236081
[TBL] [Abstract][Full Text] [Related]
37. [Not Available].
Gauthier J
Bull Cancer; 2018 Dec; 105 Suppl 2():S214-S217. PubMed ID: 30686360
[TBL] [Abstract][Full Text] [Related]
38. [Cell therapy's poster child: Chimeric antigen receptor T cell therapy].
Qian L; Chen J; Wu X; Jing R; Sun J
Sheng Wu Gong Cheng Xue Bao; 2019 Dec; 35(12):2339-2349. PubMed ID: 31880140
[TBL] [Abstract][Full Text] [Related]
39. Ophthalmic Implications of Chimeric Antigen Receptor T-Cell Therapy.
Chodnicki KD; Prasad S
Semin Ophthalmol; 2021 May; 36(4):329-334. PubMed ID: 33689570
[TBL] [Abstract][Full Text] [Related]
40. Neurotoxicity-associated sinus bradycardia after chimeric antigen receptor T-cell therapy.
Catalá E; Iacoboni G; Vidal-Jordana Á; Oristrell G; Carpio C; Vilaseca A; Cabirta A; Bosch F; Tintoré M; Barba P
Hematol Oncol; 2022 Aug; 40(3):482-487. PubMed ID: 35139240
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
